Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 26

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 26
---
 appropriate, to reflect the Reverse Stock Splits. As a result of the Reverse Stock Split, the number of shares of common stock underlying the Common Warrants and Placement Agent Warrants covered by this registration statement has been proportionately reduced by a factor of 1-for-5, and the exercise price of the Common Warrants and Placement Agent Warrants has been adjusted accordingly in accordance with their terms to ensure that the aggregate exercise price remains unchanged. Pursuant to Section 3(a) of the Common Warrants and Placement Agent Warrants, which provides for proportional adjustments in the event of a stock split, stock dividend, or similar event, the number of shares issuable upon exercise of the warrants registered for resale has been adjusted downward in the same ratio as the Reverse Stock Split, and the exercise price per share has been increased in proportion. Accordingly, all references in this prospectus to:

| ● | The                                                                                          
 number of shares of common stock underlying the Common Warrants have been updated to reflect 
 the post-split amounts.                                                                      |

| ● | The                                                                                            
 exercise price of the Common Warrants and Placement Agent Warrants has been updated to reflect 
 the adjusted per-share exercise prices after the Reverse Stock Splits.                         |

Unless otherwise indicated, all share and per-share amounts in this prospectus have been retroactively adjusted to reflect the Reverse Stock Splits. Registered Direct Offerings February 2025 Offering On February 5, 2025, we entered into a securities purchase agreement (the “February 2025 Securities Purchase Agreement”) with certain institutional investors (the “February 2025 Purchasers”) pursuant to which the Company sold, in a registered direct offering an aggregate of 300,700 shares (the “February 2025 Shares”) of common stock at a purchase price of $3.575 per share in a registered direct offering priced at-the-market under the rules of Nasdaq (the “February 2025 Offering”). The February 2025 Shares were offered pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the Securities and Exchange Commission (the “SEC”) on July 18, 2024 as supplemented by a prospectus supplement dated February 5, 2025, filed with the SEC on February 6, 2025 and accompanying base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act.

15 In a concurrent private placement, the Company also issued to the February 202